Recombinant Newcastle Disease Virus as a Vaccine Vector

Nakaya, Takaaki; Cros, Jérôme; Park, Man‐Seong; Nakaya, Yurie; Zheng, Hongyong; Sagrera, Ana María Alfaro de Prado; Villar, Enrique; García‐Sastre, Adolfo; Palese, Peter

doi:10.1128/jvi.75.23.11868-11873.2001

Cited by 225 publications

(239 citation statements)

References 36 publications

Supporting

Mentioning

223

Contrasting

Unclassified

Order By: Relevance

“…[6][7][8][9][10] A strong potential of NDV as a vaccine vector was also demonstrated. 11 SeV and most of the other mononegaviruses replicate independent of cellular nuclear functions and do not have a DNA phase in their lifecycle, and therefore are not considered to present a high risk of cell transformation by integration of the viral genetic information into the cellular genome. Thus, the feasibility of using SeV and other mononegaviruses as a novel class of vector is now increasing.…”

Section: Introductionmentioning

confidence: 99%

Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases

et al. 2004

View full text Add to dashboard Cite

Malignant tumor cells often express matrix metalloproteinases (MMPs) at a high level to enable their dissemination and metastasis. Sendai virus (SeV), a nonsegmented negative strand RNA virus, spreads in the target tissues in vivo via cleavage activation of the viral fusion glycoprotein by a tissue-specific, trypsin-like enzyme. By deleting the viral matrix protein, we previously generated a recombinant SeV that does not bud to mature virions, but is highly fusogenic and spreads extensively from cell to cell in a trypsindependent manner. Here, we changed the tryptic cleavage site of the fusion glycoprotein of this virus to a site susceptible to MMPs. The resulting recombinant virus was no longer activated by trypsin but spread efficiently in cultured cells supplemented with MMP2 or MMP9 and in human tumor cell lines expressing these MMPs. Furthermore, the virus spread extensively in tumor cells xenotrasplanted to nude mice without disseminating to the surrounding normal cells, leading to the inhibition of the tumor growth in the mice. These results demonstrate the selective targeting and killing of human tumor cells by recombinant SeV technology and greatly advance the reemerging concept of oncolytic virotherapy, which currently appears to rely largely upon a natural preference of certain viruses for cancer cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases

et al. 2004

View full text Add to dashboard Cite

show abstract

“…A recently described adenovirus expressing the HA of AIV (2) also provided full protection when injected but only partial protection when given intranasally. Because of the advent of reverse genetics for specific manipulation of nonsegmented negative-strand RNA viruses (3), HA genes derived from various influenza A viruses had been inserted into members of this order, including Rinderpest virus (4), vesicular stomatitis virus (5), and Newcastle disease virus (NDV) (6). The potential use of mass applicable recombinant poultry vaccines, such as infectious laryngotracheitis virus (ILTV) (7,8) and NDV (9) to simultaneously immunize chickens against AIV and ILTV or AIV and NDV recently has been investigated.…”

Section: T He Highly Pathogenic (Hp) Avian Influenza Virus (Aiv) H5n1mentioning

confidence: 99%

Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza

Veits

Wiesner

Fuchs

et al. 2006

Proc. Natl. Acad. Sci. U.S.A.

174

122

View full text Add to dashboard Cite

Newcastle disease virus (NDV)-expressing avian influenza virus (AIV) hemagglutinin (HA) of subtype H5 was constructed by reverse genetics. A cloned full-length copy of the genome of the lentogenic NDV strain Clone 30 was used for insertion of the ORF encoding the HA of the highly pathogenic AIV isolate A͞chicken͞ Italy͞8͞98 (H5N2) in the intergenic region between the NDV fusion and hemagglutinin-neuraminidase (HN) genes. Remarkably, two species of HA transcripts were detected in cells infected with the resultant NDVH5. In a second recombinant (NDVH5m), a NDV transcription termination signal-like sequence located within the HA ORF was eliminated by silent mutations. Consequently, NDVH5m produced 2.7-fold more full-length HA transcripts, expressed higher levels of HA, and also incorporated more HA protein into its envelope than NDVH5. NDVH5m stably expressed the modified HA gene for 10 egg passages and both recombinants were found innocuous after intracerebral inoculation of 1-day-old chickens. Immunization of chickens with NDVH5m induced NDVand AIVH5-specific antibodies and protected chickens against clinical disease after challenge with a lethal dose of velogenic NDV or highly pathogenic AIV, respectively. Remarkably, shedding of influenza virus was not observed. Furthermore, immunization with NDVH5m permitted serological discrimination of vaccinated and AIV field virus-infected animals based on antibodies against the nucleoprotein of AIV. Therefore, recombinant NDVH5m is suitable as a bivalent vaccine against NDV and AIV and may be used as marker vaccine for the control of avian influenza.vaccine ͉ recombinant Newcastle disease virus ͉ reverse genetics ͉ fowl plague

show abstract

“…This problem could be overcome by vector vaccines. The successful use of NDV as a vector for the expression of AIV HA has been described in different studies, where the foreign gene was integrated between the P and M genes (DiNapoli et al, 2010;Ge et al, 2007;Nakaya et al, 2001;Park et al, 2006) or the F and HN genes (Schröer et al, 2009;Veits et al, 2006). In both cases, the recombinant viruses conveyed protection against NDV, as well as against influenza infection of the corresponding subtype.…”

mentioning

confidence: 99%

Influence of insertion site of the avian influenza virus haemagglutinin (HA) gene within the Newcastle disease virus genome on HA expression

Ramp

Skiba

Karger

et al. 2010

Journal of General Virology

View full text Add to dashboard Cite

Recombinant Newcastle Disease Virus as a Vaccine Vector

Cited by 225 publications

References 36 publications

Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases

Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases

Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza

Influence of insertion site of the avian influenza virus haemagglutinin (HA) gene within the Newcastle disease virus genome on HA expression

Contact Info

Product

Resources

About